泊沙康唑口服混悬液在HSCT患者中的剂量校正浓度及其影响因素分析 点击下载
| 论文标题： | 泊沙康唑口服混悬液在HSCT患者中的剂量校正浓度及其影响因素分析 |
| 英文标题： | |
| 中文摘要： | 目的 分析泊沙康唑口服混悬液在造血干细胞移植（HSCT）患者中的剂量校正浓度，并分析其影响因素。方法收集2021年1月至2023年4月山东第一医科大学第一附属医院（山东省千佛山医院）收治的服用泊沙康唑口服混悬液预防侵袭性真菌病（IFD）并行泊沙康唑血药浓度监测的住院HSCT患者的临床资料。评估泊沙康唑预防IFD的浓度达标率和临床失败率，并对该药剂量校正浓度（C0/D）的影响因素进行单因素和多元线性回归分析。结果共纳入44例患者，患者的泊沙康唑平均谷浓度（C0）为（0.99±0.94）µg/mL，有20例患者的C0不低于0.7μg/mL，泊沙康唑预防IFD的浓度达标率为45.45%；13例为临床失败，临床失败率为29.55%。在C0未达标的24例患者中，有7例患者及时调整了泊沙康唑剂量，但仍有1例为临床失败；13例未进行剂量调整的患者中，有7例为临床失败；其余4例患者更换了抗真菌药物。单因素分析结果显示，患者性别、体重指数（BMI）、肾功能和联用苯妥英钠、奥美拉唑、甲氧氯普胺对泊沙康唑C0/D有显著影响（P＜0.05）；多元线性回归分析结果显示，性别、BMI和联用苯妥英钠是影响泊沙康唑C0/D的独立因素（P＜0.05）。结论泊沙康唑口服混悬液血药浓度个体差异较大；性别、BMI和联用苯妥英钠是影响泊沙康唑C0/D的独立因素。 |
| 英文摘要： | OBJECTIVE To analyze the dose-adjusted concentrations of Posaconazole oral suspension in patients undergoing hematopoietic stem cell transplantation （HSCT） and their influential factors. METHODS Data were collected from hospitalized HSCT patients admitted to the First Affiliated Hospital of Shandong First Medical University （Shandong Provincial Qianfoshan Hospital） from January 2021 to April whtwhm@yeah.net 2023 who took Posaconazole oral suspension for the prevention of invasive fungal disease （IFD） and received blood concentration of posaconazole. The rate of concentration attainment and clinical failure rate of posaconazole for the prevention of IFD were evaluated， and one-way and multiple linear regression analyses were performed for the influential factors of dose-adjusted concentrations （C0/D） of posaconazole. RESULTS A total of 44 patients were enrolled； the mean C0 of posaconazole in patients was （0.99±0.94） µg/mL， and 20 patients had a C0≥0.7 μg/mL， with a concentration attainment rate of 45.45% for the prevention of IFD； 13 cases were clinical failures， with a clinical failure rate of 29.55%. Of 24 patients who did not achieve C0/D of posaconazole for IFD prophylaxis， one patient was a clinical failure despite timely dose adjustment of posaconazole in seven patients； seven of the thirteen patients who did not undergo dose adjustment were clinical failures； and the remaining four patients were switched to other antifungal agents. The results of univariate analysis showed that gender， body mass index （BMI）， renal function， combined use of sodium phenytoin， omeprazole and metoclopramide had a significant effect on the C0/D of posaconazole （P＜0.05）； the results of multivariate linear regression analysis showed that gender， BMI and combined use of sodium phenytoin were the independent factors affecting the C0/D of posaconazole （P＜0.05）. CONCLUSIONS Significant individual differences are reflected in the blood concentration of Posaconazole oral suspension； gender， BMI and combined use of sodium phenytoin are independent factors affecting the C0/D of posaconazole. |
| 期刊： | 2023年第34卷第24期 |
| 作者： | 董琳；束一朔；董中华；衣巧艳；李洪娟；顾艳；韩燕；丁国玉；赵羽琦；张潇月；李雪；林子云；穆锴；杨依磊；时海燕；王红美 |
| 英文作者： | DONG Lin，SHU Yishuo，DONG Zhonghua，YI Qiaoyan，LI Hongjuan，GU Yan，HAN Yan，DING Guoyu， ZHAO Yuqi，ZHANG Xiaoyue，LI Xue，LIN Ziyun，MU Kai，YANG Yilei，SHI Haiyan，WANG Hongmei |
| 关键字： | 泊沙康唑；剂量校正浓度；影响因素；造血干细胞移植；治疗药物监测 |
| KEYWORDS： | posaconazole； dose-adjusted concentration； influential factor； hematopoietic stem cell transplantation； therapeutic |
| 总下载数： | 81次 |
| 本日下载数： | 2次 |
| 本月下载数： | 81次 |
| 文件大小： | 619.60Kb |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！